GHK-Cu (Copper Tripeptide-1)

Quick summary

GHK-Cu (Gly-His-Lys copper complex, INCI name: Copper Tripeptide-1) is a naturally occurring tripeptide that forms a stable complex with copper(II) ions. It is found in human plasma, saliva, and urine, and is released locally at sites of tissue injury. In cosmetic products it is widely used at low concentrations for claimed skin-rejuvenating effects. In research settings it has been studied for wound healing and anti-inflammatory properties in cell culture and animal models.

GHK-Cu is not approved as a pharmaceutical drug in any jurisdiction. The FDA, EMA, MHRA, TGA, and Health Canada regulate it as a cosmetic ingredient, not a medicine. Pivotal randomised controlled trial data for any therapeutic indication do not exist in the published literature.

The discussion below covers what the published science does and does not support. Readers interested in GHK-Cu for skin care should note that cosmetic evidence and pharmaceutical evidence are distinct, and that many circulating claims extrapolate far beyond available data.

Discovery and development

GHK-Cu was first isolated and described by Loren Pickart in 1973, who identified a fraction of human plasma that promoted the survival and growth of normal liver cells in culture.^[1] Pickart later characterised the active component as the tripeptide glycyl-L-histidyl-L-lysine (GHK) and noted its high affinity for copper(II), which is present at micromolar concentrations in blood.

Subsequent work through the 1980s and 1990s established that the GHK-Cu complex could stimulate the synthesis of collagen, elastin, and glycosaminoglycans in fibroblast culture, and promote wound contraction in animal models. These findings attracted interest both from cosmetic formulators and from researchers studying chronic wound management.

Despite decades of in-vitro research and some early-phase clinical work, GHK-Cu has not progressed through Phase 3 development for any therapeutic indication. The cosmetic industry adopted it based on the in-vitro collagen data, and it now appears in numerous commercial skin care formulations marketed for anti-aging purposes.

Structure

GHK is a tripeptide with the sequence Gly-His-Lys, molecular formula C₁₄H₂₄N₆O₄, and a molecular weight of approximately 340 daltons. The copper complex (GHK-Cu) is formed when the peptide binds one copper(II) ion through coordinate bonds involving the imidazole ring of histidine, the N-terminal amine of glycine, and the deprotonated amide nitrogen of the glycine-histidine bond.

This square planar copper coordination geometry is stable at physiological pH and gives GHK-Cu a high association constant for copper(II), allowing it to function as a copper-carrier and donor in tissues. The tripeptide alone (without copper) has been described as biologically less active, though some in-vitro effects have been reported for uncomplexed GHK.

In cosmetic products, GHK-Cu is typically present at concentrations well below 0.1 %, far lower than the concentrations (micromolar to millimolar range) used in most cell culture studies.

Proposed mechanisms of action

The following mechanisms have been described in in-vitro or animal studies. Their clinical significance in humans receiving topical cosmetic applications has not been established:

• Collagen and glycosaminoglycan synthesis: GHK-Cu has been shown to stimulate collagen types I, III, and IV production in fibroblast cultures and to increase glycosaminoglycan synthesis, which is relevant to skin extracellular matrix organisation.^[2]
• Antioxidant copper transport: by chelating copper in a stable complex, GHK-Cu may deliver copper to cuproenzymes such as lysyl oxidase (which cross-links collagen and elastin) and superoxide dismutase, supporting antioxidant defence. The copper-carrier function is thought to be central to its biological activity.^[1]
• Anti-inflammatory effects: some studies in fibroblast and macrophage models report that GHK-Cu downregulates pro-inflammatory cytokines (TNF-α, IL-6) and reduces oxidative stress markers. These findings have not been replicated in well-powered human studies.^[3]
• Angiogenesis and wound healing: in animal wound models, GHK-Cu has been reported to accelerate wound closure and promote new blood vessel formation. These effects are attributed partly to stimulation of vascular endothelial growth factor (VEGF) expression.^[4],[5]

Pharmacokinetics in summary

Human pharmacokinetic data for GHK-Cu administered as a pharmaceutical product are not available in the peer-reviewed literature. The following reflects what is known from physiological studies:

• Endogenous levels: GHK plasma concentration in healthy humans declines with age, from approximately 200 ng/mL in young adults to lower levels in older age groups. This decline has been proposed (but not proven) to be relevant to age-related changes in wound healing and skin quality.
• Topical penetration: the tripeptide is small enough to penetrate the stratum corneum to some extent, but depth of penetration and dermal bioavailability from cosmetic formulations have not been quantified in peer-reviewed clinical pharmacology studies.
• Systemic absorption from topical use: not characterised. Given the low concentrations used in cosmetics and the molecular size of the tripeptide, systemic exposure from topical application is expected to be minimal, though this has not been formally measured.

Research overview

The published clinical literature on GHK-Cu as a therapeutic agent is limited to small observational studies and early-phase work:

• Wound healing: small controlled studies in the 1990s and 2000s assessed GHK-Cu in venous stasis ulcers and surgical wounds, reporting improvements in wound area and healing rate. Sample sizes were small and methodological quality varied; no large RCT has replicated these findings.
• Skin aging (cosmetic studies): several small industry-sponsored studies have reported improvements in skin texture, wrinkle depth, and skin density following topical GHK-Cu application over 8–12 weeks. These studies typically lack adequate controls or blinding and cannot be used to draw firm conclusions about efficacy.
• Hair loss: animal and in-vitro studies suggest GHK-Cu may stimulate hair follicle growth. No peer-reviewed randomised controlled trial in humans for hair loss has been published.

The body of literature that is sometimes cited to support wide-ranging claims about GHK-Cu consists predominantly of in-vitro and rodent studies, frequently from a small number of research groups. Independent replication of key findings in human trials is sparse.^[3]

Safety overview

GHK-Cu used in cosmetic formulations at standard concentrations appears well tolerated based on decades of consumer use, with no pattern of serious adverse effects reported in the cosmetic literature or pharmacovigilance databases. The following points apply:

• Topical cosmetic use: generally regarded as safe at concentrations used in commercial skin care products. Contact allergy has been reported rarely.
• Copper toxicity: at high concentrations, free copper(II) is cytotoxic. GHK-Cu provides a stabilised, buffered form of copper, and the concentrations in cosmetics are far below cytotoxic thresholds. Systemic copper toxicity from topical application is not a recognised concern at cosmetic concentrations.
• Injectable use: safety data for subcutaneous or intravenous administration of GHK-Cu outside formal clinical trials are not available. Injectable research-grade peptides carry additional risks related to sterility, purity, and endotoxin content that are not present with pharmaceutical-grade products.

Regulatory status

GHK-Cu occupies cosmetic ingredient status in all major jurisdictions and is not approved as a pharmaceutical in any of the five regions covered by this hub:

• United States (FDA): regulated as a cosmetic ingredient under FDA Cosmetics rules. Not an approved drug. No NDA for any therapeutic indication has been approved.
• European Union (EMA / EU Cosmetics Regulation): listed as Copper Tripeptide-1 in the EU cosmetic ingredient database. No EMA marketing authorisation as a medicinal product.
• United Kingdom (MHRA / UK Cosmetics Regulation): cosmetic ingredient status retained post-Brexit. Not authorised as a medicine by MHRA.
• Australia (TGA): not registered as a therapeutic good. Used in cosmetics under Australian cosmetics rules.
• Canada (Health Canada): used in cosmetics under the Cosmetic Regulations. Not an approved drug.

Any products making therapeutic claims (rather than cosmetic claims) about GHK-Cu in these jurisdictions would be subject to pharmaceutical regulation and would require marketing authorisation that does not currently exist.